As shown in Figure S6, Supporting Information, OM (at the dose of 10 mg kg−1 via intratracheal instillation) could effectively reduce lung inflammation by inhibiting inflammatory cell infiltration, especially neutrophiles, and decreasing the pro‐inflammatory cytokine IL‐1β production in the bronchoalveolar lavage fluid (BALF). The gene discussed is IL1B; the disease is ocular melanoma.